These PFS results were significantly shorter than others reported in patients with HER2-positive advanced breast cancer in a similar second-line setting, suggesting the aggressiveness of primary trastuzumab resistance and needing more investigations. The gene discussed is ERBB2; the disease is breast carcinoma.